Anifrolumab denied as non-formulary by Cigna?

Cigna's specific coverage criteria for anifrolumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Anifrolumab as Non-Formulary

A non-formulary denial means anifrolumab is not included on Cigna's standard drug list for your plan tier, or it sits at a tier requiring additional authorization before the plan will cover it at any level. This is a plan-design decision, not a clinical judgment — it does not mean the drug is inappropriate. Non-formulary denials are among the most commonly appealed and overturned denial types, particularly for specialty biologics with narrow FDA indications where formulary alternatives either do not exist or have already been tried.

## Why This Denial Is Appealable

When no therapeutically equivalent formulary alternative exists for a specific approved indication, most plans are required to provide access through an exceptions process. Anifrolumab has a specific mechanism of action (type I interferon receptor blockade) that differs from other SLE agents; if the patient has not responded to, or cannot tolerate, available formulary options, a formulary exception is the appropriate pathway.

## Your Federal Appeal Rights

• Formulary exception / internal appeal: File a written formulary exception request supported by clinical documentation. Under ACA §2719 and applicable state external-review statutes, you also retain the right to independent external review.
• Expedited review: If the patient's condition is unstable or deteriorating, request expedited processing — plans must respond within 72 hours for urgent cases.
• External review window: Approximately four months from the date of a final internal denial. Do not let this deadline pass before escalating.

## Documentation to Gather

1. Formulary alternative trial history — for each alternative drug on Cigna's formulary that treats SLE, document: name, dates of use, reason for discontinuation (inadequate response, intolerance, clinical contraindication per prescriber). 2. Diagnosis and severity confirmation — rheumatologist notes confirming moderate-to-severe SLE, disease-activity scoring, organ involvement. 3. Prescriber letter of medical necessity — explicitly stating why anifrolumab is required for this patient and why no currently covered formulary agent is clinically appropriate. 4. FDA prescribing label — attach or cite the approved indication to demonstrate this is not an off-label use. 5. Cigna's exception criteria — obtain these from the Summary of Benefits or formulary exception form and map each requirement to the clinical record.

## Criteria-Mapping Structure

Your appeal letter should address each exception criterion Cigna lists in its formulary exception policy. For each criterion, quote the requirement, then cite the specific chart entry or document that satisfies it. Where a formulary alternative was tried and failed, include the date range and the prescriber's documented reason for discontinuation. A well-mapped exception request eliminates the reviewer's ability to deny on a technicality.